Invokamet XR is a combination medication that contains two active ingredients: metformin extended-release (XR) and canagliflozin [1][2]. It is prescribed to help manage blood sugar levels in adults with type 2 diabetes mellitus [1].
What is Invokamet XR used for?
Invokamet XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [1][2]. It is typically used when metformin alone or canagliflozin alone does not adequately control blood sugar [1].
How does Invokamet XR work?
Invokamet XR combines two mechanisms to lower blood glucose. Metformin extended-release works by decreasing glucose production by the liver and reducing glucose absorption in the intestines [3]. Canagliflozin, on the other hand, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by blocking the reabsorption of glucose in the kidneys, causing excess glucose to be eliminated from the body through urine [3][4].
What are the active ingredients in Invokamet XR?
The active ingredients in Invokamet XR are metformin hydrochloride extended-release and canagliflozin [1][2].
What doses of Invokamet XR are available?
Invokamet XR is available in multiple dosage strengths, combining different amounts of metformin XR and canagliflozin. Common strengths include 1000 mg/100 mg, 1000 mg/300 mg, and 500 mg/150 mg (metformin XR/canagliflozin) [1][5].
What are the potential side effects of Invokamet XR?
Common side effects of Invokamet XR can include diarrhea, nausea, vomiting, abdominal pain, headache, and upper respiratory tract infections [1]. More serious side effects may include lactic acidosis (a rare but serious complication of metformin), dehydration, serious urinary tract infections, and genital yeast infections [1][6]. Canagliflozin also carries a risk of increased LDL cholesterol and, in rare cases, diabetic ketoacidosis [4][6].
When does the patent for Invokamet XR expire?
Information regarding the specific patent expiry dates for Invokamet XR is maintained by DrugPatentWatch.com. This resource tracks patent lifecycles for pharmaceutical products [7].
Are there generic versions of Invokamet XR?
As of recent information, generic versions of Invokamet XR are becoming available or are being developed. The availability of generics typically follows the expiration of key patents and regulatory approvals [7].
Who makes Invokamet XR?
Invokamet XR is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [8].
What is the difference between Invokamet XR and other diabetes medications?
Invokamet XR offers a dual mechanism of action by combining metformin and canagliflozin. This differs from medications that work through a single pathway, such as DPP-4 inhibitors or sulfonylureas. Its SGLT2 inhibitor component is unique among combination therapies involving metformin, providing a distinct way to lower blood glucose by increasing urinary glucose excretion [4].